Delayed notice of non-bioequivalence test items in dispute

Published: 2002-02-20 06:57:00

Updated: 2002-02-20 06:57:00

The Korean Pharmaceutical Association (KPA) has recently contended that although the drug items subject to the bioequivalence tests were already designated by the Korean Food and Drug Administration (KFDA), its delayed notice of other items excluding from the bioequivalence tests has prevented ma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK